Related Experiment Videos
Hormonal therapy in endometrial carcinoma
1Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN 55905.
Summary
Hormonal therapy for endometrial cancer shows limited success. Identifying progesterone receptor-rich tumors improves response rates, but further research is needed for better survival outcomes.
Area of Science:
- Oncology
- Endocrinology
Background:
- Hormonal agents have been used for endometrial cancer for decades with limited improvement in response rates.
- Patient selection and differing response criteria contribute to variability in treatment outcomes.
Purpose of the Study:
- To evaluate the effectiveness of hormonal therapy in endometrial cancer.
- To identify patient subgroups that may benefit from specific hormonal treatments.
Main Methods:
- Review of existing literature on hormonal therapy for endometrial cancer.
- Analysis of response rates based on tumor characteristics, particularly progesterone receptor levels.
- Consideration of antiestrogens and combination therapies.
Main Results:
- Progestational agents show a 72% response rate in progesterone receptor-rich tumors.
- Responses have also been observed with antiestrogens and combination therapies.
- Limited duration of objective responses and poor long-term survival remain challenges.
Conclusions:
- Progesterone receptor levels can help identify patients sensitive to hormonal therapy.
- While encouraging, current hormonal therapies have limitations in improving long-term survival.
- Further rigorous studies are needed to optimize hormonal treatment strategies for endometrial cancer.